RT journal article
T1 Autoimmune diseases induced by TNF-targeted therapies
A1 Ramos Casals, Manuel
A1 Brito Zerón, Pilar
A1 Soto Cardenas, María José
A1 Cuadrado, Maria Jose
A1 Khamastha, Munther A.
A2 Cirugía
A2 Medicina
K1 adalimumab
K1 anti-TNF
K1 etanercept
K1 infliximab
K1 interstitial lung disease
K1 lupus
K1 thrombosis
K1 vasculitis
AB Anti-TNF agents are increasingly being used for a rapidly expanding number of rheumatic and systemic autoimmune diseases. As a result of this use, and of the longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. The clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of autoimmune diseases developing after TNF-targeted therapy, were analyzed through a baseline Medline search of articles published between January 1990 and May 2008 (www.biogeas.org). A total of 379 cases of autoimmune diseases secondary to TNF-targeted therapies were identified. The anti-TNF agents were administered for rheumatoid arthritis in more than 80% of cases. The use of anti-TNF agents has been associated with an increasing number of cases of autoimmune diseases, principally cutaneous vasculitis, lupus-like syndrome, systemic lupus erythematosus and interstitial lung disease. Other autoimmune diseases associated with TNF-targeted therapies have been recently described, e.g. sarcoidosis, antiphospholipid syndrome-related features, and autoimmune hepatitis or uveitis. Large, prospective, postmarketing studies are required to evaluate the risk of developing autoimmune diseases in patients receiving TNF-targeted therapies.
PB Elsevier
SN 1521-6942
YR 2008
FD 2008-10
LK http://hdl.handle.net/10498/39207
UL http://hdl.handle.net/10498/39207
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 06-nov-2026